Delving into the Latest Updates on Cephalexin with Synapse

Overview

Basic Info

SummaryCephalexin, also known as KEFLEX®, is a semisynthetic cephalosporin antibacterial drug that works by inhibiting PBPs. It was first approved in 1971 in the US by Pragma Pharmaceuticals LLC for oral administration. Cephalexin is used to treat various bacterial infections such as respiratory tract infections, otitis media, skin and skin structure infections, bone infections, and genitourinary tract infections. Its molecular formula is C16H17N3O4S•H2O with a molecular weight of 365.41. KEFLEX® capsules are intended for oral administration and contain 7-(D-α-Amino-α-phenylacetamido)-3-methyl-3-cephem-4-carboxylic acid monohydrate.

Drug Type

Small molecule drug

Synonyms

Ammonia benzyl cephalosporin, Cafalexin, Cefaiexin

+ [22]

Target

PBPs

Action

inhibitors

Mechanism

PBPs inhibitors(Bacterial penicillin-binding protein inhibitors), Cell wall inhibitors

Therapeutic Areas

Infectious DiseasesHemic and Lymphatic DiseasesMouth and Tooth Diseases+ [5]

Active Indication

Acute bacterial sinusitisAcute prostatitisBacterial otitis media+ [16]

Inactive Indication

AnaphylaxisUrogenital Abnormalities

Originator Organization

Pragma Pharmaceuticals LLC

Active Organization

Aspen Pharmacare Australia Pty Ltd.

Kyowa Pharmaceutical Industry Co., Ltd.

FUJIFILM Toyama Chemical Co., Ltd.

+ [1]

Inactive Organization

Eli Lilly & Co.

Pragma Pharmaceuticals LLC

Drug Highest PhaseApproved

First Approval Date

United States (04 Jan 1971),

AnaphylaxisInfectious DiseasesOtitis Media+ [4]

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC16H19N3O5S

InChIKeyAVGYWQBCYZHHPN-CYJZLJNKSA-N

CAS Registry23325-78-2

Cephalosporin antibiotics are commonly used but can result in allergic reactions and anaphylaxis. There is no clear diagnostic approach for cephalosporin-allergic patients, and guidance for the use of other antibiotics in allergic patients is based on side chain chemical similarity and limited skin testing evidence. This project includes a clinical trial and mechanistic studies to optimize the approach to cephalosporin allergy and advance future diagnostics.

Start Date01 Feb 2025

Sponsor / Collaborator

The General Hospital Corp.

[+1]

NCT04401553

/ WithdrawnPhase 4IIT

First Tier Versus Second Tier Antibiotics for Surgical Site Infections Following Hysterectomy In the Patients With a Beta-Lactam Allergy: A Prospective, Randomized, Single-Blinded Clinical Trial

Postoperative surgical site infection (SSI) is associated with unnecessary use of heath care resources including prolonged hospitalization and increased hospital readmission. Perioperative antibiotic prophylaxis is one of the most important strategies for prevention of SSI. If there is a beta-lactam allergy, second tier antibiotics (vancomycin and clindamycin) are recommended alternatives to first- and second-generation cephalosporins because of fears of possible allergy.
This prospective, randomized, and single-blinded clinical trial is designed to examine causality between second tier antibiotics use and surgical site infections in the subjects with a documented unverified penicillin allergy. Unverified beta-lactam allergy could be associated with antimicrobial treatment failure with second tires antibiotics during postoperative period.

Start Date16 Aug 2024

Sponsor / Collaborator

The University of Texas Southwestern Medical Center

NCT06336824

/ RecruitingPhase 3IIT

Early Intravenous to Oral Antibiotic Switch in Uncomplicated Staphylococcus Aureus Bacteraemia: The EVOS Randomized Controlled Trial

The Early Intravenous to Oral Antibiotic Switch in Uncomplicated Staphylococcus aureus Bacteraemia (EVOS) study is a multicentre, randomized, open-label, parallel group, phase 3, non-inferiority trial of early intravenous to oral antibiotic switch in comparison with standard intravenous antibiotic regime among patients with uncomplicated Staphylococcus aureus bacteraemia (SAB). The study is based on the hypothesis that an early switch from IV to oral antimicrobial therapy is non-inferior and safe compared to conventional minimum 14-day course of IV therapy in patients with low-risk uncomplicated SAB.

Start Date28 Jun 2024

Sponsor / Collaborator-

100 Clinical Results associated with Cephalexin

Login to view more data

100 Translational Medicine associated with Cephalexin

Login to view more data

100 Patents (Medical) associated with Cephalexin

Login to view more data

9,723

Literatures (Medical) associated with Cephalexin

01 Jul 2025·SEPARATION AND PURIFICATION TECHNOLOGY

Enhanced degradation of Cephalexin via peracetic acid activation using NiCo2O4 in different dimensional morphologies: Mechanistic insights and environmental implications

Author: Chen, Linjer ; Dong, Cheng-Di ; Chen, Chiu-Wen ; Nguyen, Thanh-Binh ; Le, Van-Re ; Pham, Tien-Duc

This study investigates the synthesis and application of NiCo₂O₄ with distinct morphologies-nanorods (1D), nanosheets (2D), and flower-like structures (3D)-to enhance peracetic acid (PAA) activation for the degradation of the antibiotic cephalexin (CPX).The 3D NiCo₂O₄ morphol. demonstrated superior properties, including enhanced crystallinity, electron transfer capabilities, and oxygen vacancies, which collectively improved the generation of reactive oxygen species.This led to a significant increase in CPX degradation efficiency within the PAA system.The 3D NiCo₂O₄/PAA system achieved an impressive 97.5% degradation of CPX and notable mineralization within 30 min.The kinetic rate constant (kobs) for CPX degradation in the 3D system was 2.8 times higher than the 2D system and 8.5 times higher than the 1D system.Both radical (O^-₂, OH, and R-O) and non-radical (¹O₂) contributed to the degradation process, with ¹O₂ being the primary contributor.Addnl., this study explored parameters such as mineralization, catalyst reusability, intermediate toxicity, and degradation pathways, highlighting the potential of NiCo₂O₄ morphologies in environmental pollutant removal.

01 Jun 2025·FOOD MICROBIOLOGY

Isolation and characterization of Salmonella Typhimurium SL1344 variants with increased resistance to different stressing agents and food processing technologies

Article

Author: Nadal, L ; Mañas, P ; Halaihel, N ; Cebrián, G ; Guillén, S

In this study, resistant variants of Salmonella enterica serovar Typhimurium SL1344 to different stressors were selected. In addition, a genetic and phenotypic study was performed to explore the mechanisms underlying the acquisition of resistance. We isolated 4 variants with increased stable resistance to acid, osmotic stress, high hydrostatic pressure (HHP) and Ultraviolet-C light (UV-C) after repeated rounds of exposure to these agents and outgrowth of survivors. A PEF-resistant variant (SL1344-RS), previously isolated by Sagarzazu et al. (2013), was also included in the analysis. The results indicated that the isolated variants showed resistance to at least one other agent. This increased resistance, in general terms, had a fitness cost in growth, and exerted a variable impact on virulence (mainly in cell adhesion capacity), increased antibiotic resistance but did not influence in biofilm formation capacity. Whole Genome Sequencing (WGS) analysis allowed us to identify the genetic changes responsible for these phenotypic differences, and revealed that in 3 out of the 5 variants (including SL1344-RS) a mutation was found in hnr gene, an anti-sigma factor that promotes RpoS proteolysis. Hence the expression of several rpoS-regulated genes was quantified and found higher in these variants. This increase in RpoS activity would explain the lower growth rates observed in these 3 variants, as it would lead to increased transcription of genes involved in growth arrest and resistance to various types of stress. However, further analysis of a set of 22 additional Salmonella strains obtained from different culture collections indicated that a direct relationship between RpoS activity and stress resistance might not exist within Salmonella.

01 Apr 2025·SEPARATION AND PURIFICATION TECHNOLOGY

The efficient degradation of carbamazepine by Cu-Fe bimetallic composite carbon derived from the waste cation exchange resins: Mechanism, ecotoxicity, and continuous flow catalysis

Author: Han, Zhengyu ; Pan, Fei ; Yang, Kun ; Ye, Yuxuan ; Li, Haochen ; Wu, Longli ; Li, Qiang ; Wang, Rongling ; Li, Xinyu ; Wu, Jiahui ; Zong, Xiaofei

The Cu-Fe bimetallic composite carbon (CuFeO₂@CR) was synthesized by using the waste cation exchange resins as the carbon source to degrade carbamazepine (CBZ) by activating peroxymonulfate (PMS).Results found that 91.3% of CBZ was degraded under the optimal condition ([PMS] = 0.2 g/L, [CuFeO₂@CR] = 0.3 g/L, T = 25°C).CuFeO2@CR could efficiently degrade CBZ at pH 3.03-9.02 and maintain the degradation at 83.6% in the fifth cycle.The reactive oxygen species (ROS) were SO.-4, .OH, and ¹O₂ with the relative contribution of 35%, 29%, and 36%, resp.DFT calculation demonstrated that CuFeO₂@CR exhibited a preferential affinity for PMS and greater transfer electrons capacity than CR.Three reaction pathways were proposed in the CuFeO₂@CR/PMS system, and the degradation could effectively reduce the toxicity into non-toxic.The continuous flow catalytic experiment indicated the promising application in the treatment of antibiotic wastewater.This work provides guidance and theor. support for CBZ degradation mechanisms.

4

News (Medical) associated with Cephalexin

08 Mar 2023

·endpts.com

FDA inspection uncovers cherry-colored antibiotic residue on equipment at Teva's New Jersey site

An FDA inspection report on Teva’s manufacturing site in New Jersey has revealed issues with both equipment cleaning and quality. The three-page report , which was obtained by Endpoints News via a FOIA request from the FDA, showed several observations from its inspection, which took place between Nov. 1 and Nov. 10 of last year, at Teva’s site in Fairfield, NJ. Inspectors noted a buildup of “unknown residue” within two production rooms that had been documented as cleaned. Specifically, a pink- or red-colored residue was found on equipment in the mixing room that had most recently been used to manufacture Cefadroxil tablets. Cefadroxil, which is used to treat bacterial infections in various parts of the body, does not use any dyes or flavorings. Previously, the same equipment also produced several batches of Cephalexin, another antibiotic which does include a cherry flavoring and a red dye, FDA said. Cephalexin is used to treat pneumonia, respiratory infections and others. The report also indicates that several other areas of the mixing room contained unknown residue, including a workstation and several blenders, one of which had previously been used to make Cephalexin capsules. The inspection report also said that some Cephalexin tablets had two complaints attached, which was part of a larger investigation into “defective coating.” As part of the investigation, the batch was subjected to other tests, but was also run through screening equipment that was not documented as “qualified with tablet products.” The report and the standard operating practices don’t give details on the screening of tablets. While over 34,000 tablets were rejected, the remaining tablets that were scanned were released for distribution in the US in 2018. Teva also received 30 complaints related to defective coatings on Cephalexin between Nov. 2018 and March 2021. Coating enhancements were recommended, while the implementation of these enhancements is still pending, according to the report. Endpoints reached out to Teva for a statement on this report but did not receive a response by press time. Teva’s manufacturing sites have been under the FDAs microscope in the past. In 2021 , investigators unveiled several problems at a Teva Pharmaceuticals plant in Irvine, CA, including mold stemming from water leaks. Teva halted production at that site, which eventually led to the recall of 2.5 million vials of drugs, according to a Bloomberg report . That site was shuttered in August of 2022, with 305 people being laid off.

17 Feb 2021

·www.biospace.com

Increasing Awareness About New Skin Care Treatments is Pushing Growth of Necrotizing Skin Infections Treatment Market to Newer Heights, Finds Fact.MR

Common symptoms of necrotizing skin infection include onset of pain and swelling at the site of wound, nausea, ulcer, fever etc. Necrotizing skin infections includes various necrotizing forms of fasciitis, myositis and cellulitis. The treatment of necrotizing skin infections is surgically removal of dead and septic tissues and various range of antibiotics. The major potential end users for necrotizing skin infection treatment market where these treatments are high in demand and generate significant revenues includes hospital associated hospitals, specialty clinic and ambulatory surgery centers and research institutes. For more insights into the Market, Request a Sample of this Report - The global market for necrotizing skin infection treatment is expected to register a moderate growth rate over the forecast period on the account of increase in number of diagnostic tests performed in humans. Different types of products are being introduced in the necrotizing skin infection treatment market recently by leading players such as anti-infective Aganocide compound for necrotizing skin infection known as Neutro phase skin and wound cleanser by Novabay pharmaceutical Inc., and some of the innovative surgical methods for treating severe cases of necrotizing skin infection are expected to come in the necrotizing skin infection treatment market. Thus there exists a high competition among local and regional players for necrotizing skin infection treatment market. What Drives Global Market? According to CDC (center for Disease Control and Prevention) necrotizing fasciitis is caused majorly by group A streptococcus and is very common infection among necrotizing skin infections. Among the oral antibiotic treatment indicated for group A streptococcus, the Amoxicillin or cephalexin medicinal product segment is expected to lead the global necrotizing skin infection treatment market over the forecast period. Diagnostic laboratories and specialty clinics is expected to contribute high revenue share in the global necrotizing skin infection treatment market as they are the most significant platform to perform diagnostic tests and provide treatment for necrotizing skin infection. Hospital for treating necrotizing skin infections also account for significant revenue generation owing to large footprint of patients to get treated. The growing demand for effective cure indicated for necrotizing skin infections as current standard cure for necrotizing skin infections also involves surgical debridement unfortunately leading to amputations. To prevent loss of limb or fatal outcome need for new therapies in necrotizing skin infection market is expected to be the major factor driving the growth of the necrotizing skin infection market over the forecast period. Also, rapid discovery of novel therapy like hyperbaric oxygen therapy is further expected to drive the revenue growth in global necrotizing skin infection treatment. View Detailed Table of Content Here: How Health-Tech Advancements Influencing Market Development? Increase in advance diagnostic technique for diagnosis of necrotizing skin infection like magnetic resonance imaging is also contributing to the growth of necrotizing skin infection treatment market. Approval and launch of new medicines by leading companies is the other important factor fueling to the growth of the global necrotizing skin treatment market. However, improper diagnosis of necrotizing skin infection is anticipated to restrain the revenue growth in global necrotizing skin infection treatment market. As early symptoms of necrotizing skin diseases are often mistaken for flu. The global necrotizing skin infection treatment market is fragmented with few number of domestic manufacturers. Examples of some of the key players operating in the global necrotizing skin infection treatment market are DURATA therapeutics, cubist Pharmaceutical, Wockhardt limited, Atox Bio Inc., Basilea pharmaceutical, AG and Melinta Therapeutics,Inc. and others. Request Methodology on this Research Report for specific research solutions: Explore Fact.MR’s Lucid Healthcare Coverage Dental Restoratives Market – The prevalence and severity of dental decay has waned over the past few years. Dental care needs have engendered a significant shift in the nature of dental care services- from conventional restorative care to cosmetic and preventive services. This shifting trend has propelled dental service providers to develop technologically advanced contraptions. Aptamer Market – Continuous advancements in selection technique remain a critical lever to the growth of the aptamer market. The conventional Systemic Evolution of Ligands by Exponential Enrichment (SELEX) technique included lengthy iterative steps, which would delay probe selection and further slowdown the selection process. About Fact.MR Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. We have offices in US and Dublin, whereas our global headquarter is in Dubai. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Reach out to us with your goals, and we’ll be an able research partner. Contact: Sudip Saha US Sales Office: 11140 Rockville Pike Suite 400 Rockville, MD 20852 United States Tel: +1 (628) 251-1583 E: sales@factmr.com Corporate Headquarter: Unit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A, Jumeirah Lakes Towers, Dubai, United Arab Emirates

06 Sep 2017

·www.bioportfolio.com

Yungjin Pharm Co Ltd 003520 Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 22082017] Prices from USD $250

Summary Yungjin Pharm Co Ltd Yungjin, a subsidiary of KTG Corp is a pharmaceutical company that develops, manufactures and distributes active pharmaceutical ingredients, formulations and tonic drinks. The company's API products include cephalosporins and other general products. It also provides cefaclor cap and dry syr, cefadroxil monohydrate, cefalexin monohydrate, cefamandole inj, cefcapene pivoxil tab and fine gran, cefmetazole inj, cefminox inj, cefotaxime inj, and cefatrizine propylene glycolate, among others. Yungjin offers formulation products for various therapeutic areas such as antibiotics, CNS, cardiovascular, endocrine system, respiratory, antiinflammatory and analgesics, antihistamine, antifungal, total nutrition, urinary system, vitamin and supplement, and cosmetics. The company also provides tonic drinks with pidotimod liquid. It operates through research and development institute, and factory located in Korea. Yungjin is headquartered in Seoul, South Korea. Yungjin Pharm Co Ltd 003520 Pharmaceuticals Healthcare Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions MAs, partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, subsector and regions. GlobalData derived the data presented in this report from proprietary inhouse Pharma eTrack deals database, and primary and secondary research. Scope Financial Deals Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships. Deals by Year Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period. Deals by Type Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. Deals by Region Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America. Deals by Subsector Chart and table showing information on the number of deals and value reported by the company, by subsector. Major Deals Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's major public companies key financial metrics and ratios. Business Description A brief description of the company's operations. Key Employees A list of the key executives of the company. Important Locations and Subsidiaries A list and contact details of key centers of operation and subsidiaries of the company. Key Competitors A list of the key competitors of the company. Key Recent Developments A brief on recent news about the company. Reasons to Buy Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period. Understand the company's business segments' expansion / divestiture strategy The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy. Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios. Equip yourself with detailed information about the company's operations to identify potential customers and suppliers. The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors. Stay uptodate on the major developments affecting the company Recent developments concerning the company presented in the profile help you track important events. Gain key insights into the company for academic or business research Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs. Note*: Some sections may be missing if data is unavailable for the company.

Acquisition

100 Deals associated with Cephalexin

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D00906	Cephalexin	J01DB01	DB00567

R&D Status

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Acute bacterial sinusitis	Australia	Aspen Pharmacare Australia Pty Ltd.	24 Feb 2004
Acute prostatitis	Australia	Aspen Pharmacare Australia Pty Ltd.	24 Feb 2004
Bacterial otitis media	Australia	Aspen Pharmacare Australia Pty Ltd.	24 Feb 2004
Beta-hemolytic Streptococcus infection	Australia	Aspen Pharmacare Australia Pty Ltd.	24 Feb 2004
Complicated skin and soft tissue infection	Australia	Aspen Pharmacare Australia Pty Ltd.	24 Feb 2004
Pneumococcal Infections	Australia	Aspen Pharmacare Australia Pty Ltd.	24 Feb 2004
Bacterial Infections	China	Maoxiang Group (Tianjin) Pharmaceutical Co Ltd	01 Jan 1981
Acute Bronchitis	Japan	Kyowa Pharmaceutical Industry Co., Ltd.	01 Aug 1978
Cystitis	Japan	Kyowa Pharmaceutical Industry Co., Ltd.	01 Aug 1978
Lymphadenitis	Japan	Kyowa Pharmaceutical Industry Co., Ltd.	01 Aug 1978
Otitis Externa	Japan	Kyowa Pharmaceutical Industry Co., Ltd.	01 Aug 1978
Pharyngolaryngitis	Japan	Kyowa Pharmaceutical Industry Co., Ltd.	01 Aug 1978
Pneumonia	Japan	Kyowa Pharmaceutical Industry Co., Ltd.	01 Aug 1978
Pyoderma	Japan	Kyowa Pharmaceutical Industry Co., Ltd.	01 Aug 1978
Secondary infection	Japan	Kyowa Pharmaceutical Industry Co., Ltd.	01 Aug 1978
Sinusitis	Japan	Kyowa Pharmaceutical Industry Co., Ltd.	01 Aug 1978
Tonsillitis	Japan	Kyowa Pharmaceutical Industry Co., Ltd.	01 Aug 1978
Inflammation	Japan	FUJIFILM Toyama Chemical Co., Ltd.	04 Apr 1972
Anaphylaxis	United States	Pragma Pharmaceuticals LLC	04 Jan 1971
Infectious Diseases	United States	Pragma Pharmaceuticals LLC	04 Jan 1971

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


AAAAI2024	Not Applicable	Anaphylaxis	-	Cefazolin	ulsyjzfsgh(plkfvxexat) = awgpmfdhjj ykiixqesar (ffcedfzsqe )	-	23 Feb 2024
				Cefoxitin	ulsyjzfsgh(plkfvxexat) = giozsvtahf ykiixqesar (ffcedfzsqe )
NCT02579161 (CTgov)	Phase 3	Kidney Calculi	98	Fluoroquinolones+cephalosporins+Gentamicin+Ampicillin+Clindamycin (Antibiotics for a 24 Hour Period)	fllwbifjly = mbdtwzeqrh kdxjtraehj (tjokorwsbk, qryacdeuou - hfmahgnjbp) View more	-	14 Mar 2023
				Fluoroquinolones+cephalosporins+Gentamicin+Ampicillin+Clindamycin (Continued Antibiotics)	fllwbifjly = jopgizrreh kdxjtraehj (tjokorwsbk, dbavtcdiip - qqsjobztml) View more
AAAAI2023	Not Applicable	Allergy to penicillin	-	Cephalosporins	evoifuklky(lbnisbighr) = wlvaiskbhb jzzatxkmow (rsqayjbcba )	-	01 Feb 2023
AAAAI2023	Not Applicable	Anaphylaxis	220	Cephalosporins (Direct GOC challenge)	wgulycextu(hlldmmpnol) = ygdbfchadc vuvlwxhtgi (cbovxfapmd ) View more	-	01 Feb 2023
NCT04471246 (Pubmed \| CJEM)	Phase 4	Cellulitis	69	High-dose cephalexin (1000 mg)	vxmdrtqicm(kfceitlmpj) = bwvdgduihp neqzzcrbbh (kzoifuwnkr, 43.1 - 59.8)	-	02 Jan 2023
IRCT20200608047685N2 (Pubmed)	Phase 3	Obesity	-	Oral cephalexin and metronidazole	ezhvtpxihb(sxmzueknzm) = azawkgfiud nmshtzojmg (pbqexmaxfm ) View more	Positive	05 Dec 2022
				Cephalexin and placebo	ezhvtpxihb(sxmzueknzm) = ihhgzvesrl nmshtzojmg (pbqexmaxfm ) View more
NCT01595529 (SCOUT, CTgov)	Phase 2	Urinary Tract Infections	717	Cephalexin+Trimethoprim-sulfamethoxazole (TMP-SMX)+Sulfamethoxazole+Trimethoprim+Cefdinir+Cefixime (Standard Course Treatment)	duikgsaleg = zgekfdsged sdbqpktwxd (pubpzopgra, pnhfolczsn - btindasdlo) View more	-	13 Jul 2020
				placebo (Short Course Treatment)	duikgsaleg = vekghytrth sdbqpktwxd (pubpzopgra, vyhxcremwb - srvpeptqze) View more
P0300 (ERA2020)	Not Applicable	PMRG-producing bacteria \| extended spectrum beta-lactamases producers (ESBLs) \| PMQR	105	Cephalosporins	tmxrvqhxhr(bcxnsaclfb) = wtaxuibmpl vmutrjgcpw (swoexrylnv, 0.495%CI[0 - 21;0 to 75]) View more	Negative	06 Jun 2020
				Fluoroquinolones	tmxrvqhxhr(bcxnsaclfb) = ewztczifgd vmutrjgcpw (swoexrylnv, 0.495%CI[0 - 21;0 to 75]) View more
NCT00957827 (CTgov)	Not Applicable	Lacerations	4	keflex (Keflex)	nmgnmnfrbg(xapmlrlunv) = kbmndismbb wjpqqkynxg (yvepekydgy, snjvqyuhrp - nczawclncj) View more	-	16 Apr 2019
				placebo (Placebo)	nmgnmnfrbg(xapmlrlunv) = klgnrailyq wjpqqkynxg (yvepekydgy, ywsjrauusr - yebdxdnccl) View more
NCT01029782 (CTgov)	Phase 2	Cellulitis	206	cephalexin+cefazolin+probenecid (IV Cefazolin Plus Oral Probenecid and Placebo Cephalexin)	lrfbjdpjnf = hkxbpjzdwm rdkxvvclgo (bypzxueboc, hesvtbnsxd - shsorcfmrw) View more	-	13 Aug 2018
				Oral cephalexin (Oral Cephalexin and Saline IV Plus Probenecid Placebo)	lrfbjdpjnf = ynmjoqowvl rdkxvvclgo (bypzxueboc, fpueybfbvi - xitdqjdkip) View more